FDA commissioner nomination
The Senate Health Committee is understood to be planning a vote on FDA Acting Commissioner Lester Crawford's nomination to the permanent post for mid-May. The vote would come just over a month after an April 13 vote on Crawford was abruptly cancelled. At the time, committee staff said the cancellation was due to an eleventh-hour anonymous allegation about personal conduct that the leadership believed merited further investigation (1"The Pink Sheet" April 18, 2005, p. 4)...
You may also be interested in...
Acting FDA Commissioner Lester Crawford's prospects for Senate confirmation appear to be in jeopardy after the Health Committee disclosed concerns about a conduct allegation lodged against the nominee
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.
Roche is hoping the investigational oral drug can help it expand its presence in breast cancer and break into the prostate cancer market – but the signals are decidedly mixed.